The reducing effects of tazifylline on histamine-induced bronchoconstriction in atopic asthmatics.
Percentage reductions in the peak flow rates to a standardized number of histamine inhalations were compared after 7 days of treatment with 10 mg bd tazifylline and after 7 days of placebo in a randomized crossover study in 11 male seasonal atopic asthmatics. After tazifylline, mean % reductions in peak flow rates were significantly lower than after placebo (p = 0.03). The effects of tazifylline had disappeared within 7 days of stopping treatment. Using a 50% decrease in bronchial reactivity as the criteria of "protection", 7 of the subjects were "protected" by tazifylline only and none by placebo only (p = 0.03).
Kiviranta
K
K
Allergy Hospital, Helsinki University Central Hospital, Finland.
Stenius-Aarniala
B
B
Reuter
C
C
Harlow
B
B
Scott
J
J
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013806:Theophylline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D001993:Bronchodilator Agents; D006634:Histamine H1 Antagonists; D006632:Histamine; D013806:Theophylline; C048398:tazifylline